Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -206.55% is 40% above its 3-year average of -343.02%, near the high end of its 3-year range (-862.83%–-98.10%).
0.47% below its 12-month average of -205.58%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -59.45%.
RETURN ON ASSETS (ROA)
-206.55%
RETURN ON ASSETS (ROA) AVG TTM
-205.58%
RETURN ON ASSETS (ROA) AVG 3Y
-343.02%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-0.47%
CURRENT VS 3Y AVG
+39.79%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.14%
median of 562 covered companies
CURRENT VS SECTOR MEDIAN
-633.88%
vs the sector median at left
Cadrenal Therapeutics, Inc. Common Stock
Market Cap
$3.42M
Return on Assets (ROA)
-206.55%
TTM Avg
-205.58%
3Y Avg
-343.02%
5Y Avg
N/A
Market Cap
$3.41M
Return on Assets (ROA)
-111.26%
TTM Avg
-147.41%
3Y Avg
-127.90%
5Y Avg
-106.52%
Market Cap
$3.38M
Return on Assets (ROA)
-95.33%
TTM Avg
-115.11%
3Y Avg
-93.94%
5Y Avg
-73.81%
Market Cap
$3.47M
Return on Assets (ROA)
-67.51%
TTM Avg
-41.84%
3Y Avg
-44.47%
5Y Avg
-41.13%
Market Cap
$3.54M
Return on Assets (ROA)
-19.43%
TTM Avg
-90.07%
3Y Avg
-138.72%
5Y Avg
-110.42%
Market Cap
$3.26M
Return on Assets (ROA)
55.30%
TTM Avg
-3307.76%
3Y Avg
-1681.95%
5Y Avg
-1351.74%
Market Cap
$3.59M
Return on Assets (ROA)
-8.01%
TTM Avg
-37.73%
3Y Avg
-92.58%
5Y Avg
-74.07%
Market Cap
$3.13M
Return on Assets (ROA)
-80.08%
TTM Avg
-84.48%
3Y Avg
-250.02%
5Y Avg
-187.49%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $3.42M | -206.55% | -205.58% | -343.02% | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.41M | -111.26% | -147.41% | -127.90% | -106.52% |
| IceCure Medical Ltd (ICCM)vs › | $3.38M | -95.33% | -115.11% | -93.94% | -73.81% |
| Evogene Ltd. (EVGN)vs › | $3.47M | -67.51% | -41.84% | -44.47% | -41.13% |
| Mustang Bio, Inc. (MBIO)vs › | $3.54M | -19.43% | -90.07% | -138.72% | -110.42% |
| MBody AI Ltd. (MBAI)vs › | $3.26M | 55.30% | -3307.76% | -1681.95% | -1351.74% |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.59M | -8.01% | -37.73% | -92.58% | -74.07% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.13M | -80.08% | -84.48% | -250.02% | -187.49% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.18M | -238.27% | -211.11% | -146.32% | -173.65% |
ROA
-206.6%
ROE
-282.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -305.95% |
| 2024-12-31 | -105.21% |
| 2023-12-31 | -98.10% |
| 2022-12-31 | -862.83% |
